News & Events

Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 17, 2023

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 15, 2023

Sporos BioDiscovery to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 9, 2023

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma

Oct 27, 2022

Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium

Oct 27, 2022

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

May 26, 2022

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

Apr 21, 2022

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research

Apr 11, 2022

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Jan 12, 2022

Sporos Bioventures Announces Formation of Strategic Advisory Board

Jan 11, 2022

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors

Jan 4, 2022

Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer

Sep 19, 2021

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

Jun 24, 2021

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Jun 3, 2021

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing

May 25, 2021

Sporos Launches with $38.1 Million Series A Financing

May 6, 2021

Nirogy Therapeutics to Present at AACR Annual Meeting 2021

Apr 7, 2021

JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System

Feb 17, 2021

Nirogy Therapeutics Launches with $16.5 Million Series A Financing

Jan 26, 2021

Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum

Dec 28, 2020

New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement

Oct 9, 2020

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers

Oct 4, 2020

Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research

Jun 24, 2020

Asylia Therapeutics Moves into JLABS @TMC

Jun 6, 2020

KRLD Radio Interview: Some Covid Survivors Face Long-Term Consequences

Jun 3, 2020

CPRIT Awards $3 Million to Asylia Therapeutics

May 11, 2020

Heat Shock Protein-70 (HSP70) is an Essential Component of Anti-Tumor Immunity

May 2, 2020

Biotech on the Rise

Jan 2, 2019